Format

Send to

Choose Destination
Euro Surveill. 2017 Feb 16;22(7). pii: 30464. doi: 10.2807/1560-7917.ES.2017.22.7.30464.

Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.

Author information

1
EpiConcept, Paris, France.
2
Both authors have contributed equally to the study and manuscript writing.
3
The members of I-MOVE/I-MOVE+ study team are listed at the end of the article.

Abstract

We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0-14, 15-64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65-79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).

KEYWORDS:

ILI; SARI; immunisation; influenza; influenza like illness; severe acute respiratory infection; vaccine effectiveness; vaccines

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for European Centre for Disease Prevention and Control (ECDC) Icon for PubMed Central
Loading ...
Support Center